Sold and Supplied by Healthylife Pharmacy
This product is a Prescription Only Medicine (S4) and is sold by Healthylife Pharmacy, an independently owned and operated pharmacy business. This prescription product requires a valid Australian script.
Healthylife provides general product information such as nutritional information, country of origin and product packaging for your convenience. This information is intended as a guide only, including because products change from time to time. Please read product labels before consuming. For therapeutic goods, always read the label and follow the directions for use on pack. If you require specific information to assist with your purchasing decision, we recommend that you contact the manufacturer via the contact details on the packaging or email us at [email protected]. Product ratings and reviews are taken from various sources including Bazaarvoice. Healthylife does not represent or warrant the accuracy of any statements, claims or opinions made in product ratings and reviews.
HealthylifeStrattera (atomoxetine) is a selective norepinephrine reuptake inhibitor which is primarily indicated for the treatment of attention-deficit/hyperactivity disorder (ADHD) and other related mental/mood disorders. It works by inhibiting the reuptake of norepinephrine, a neurotransmitter associated with attention and impulse control, in the brain. By increasing norepinephrine levels in the brain, Strattera helps to improve attention and reduce impulsivity, leading to improved emotional and behavioral well-being.
Healthylife has not verified the reliability and efficacy of this product through clinical trials or available information.
Strattera (atomoxetine) is available in a strengths range from 10mg to 20mg. The starting dose is 10mg, which should be taken at the same time every day. The maximum recommended dosing frequency is once per day.
To learn more about Strattera, please visit our.
Healthylife offers a variety of therapeutic goods which are available for purchase by consumers.
Tablets are manufactured in Europe. If you are buying from a non-EU wholesaler, please contact us to obtain your requested product.
Strattera note: As of November 2023, drug manufacturer Eli Lilly and Company discontinued all strengths of Strattera from the marketplace. Strattera generic, atomoxetine, is available.
Eli Lilly and Company terminate an agreement that allowed Eli Lilly and Company to market generic Strattera (atomoxetine) to more than 25 million patients each month in the United States. Generic Strattera is indicated for the treatment of attention-deficit hyperactivity disorder, Attention-Deficit hyperactivity disorder (ADHD) other forms of attention-deficit disorder, major depressive disorder, generalized anxiety disorder, and non-any new depressive disorder.
Strattera is an antidepressant that is used to treat major depressive disorder, and generalized anxiety disorder. It is also used to treat depression in new onset anxiety disorder.
Strattera works by increasing the levels of norepinephrine and dopamine in the brain to improve attention and impulse control. It also helps improve communication between nerves in the brain to stay on top of important tasks.
The effectiveness of Strattera tablets in treating ADHD has been shown, and Strattera is considered an effective option for many adults with the disorder. Strattera is also an effective option for children with ADHD who notice speech problems.
Strattera is used for the treatment of major depressive disorder and generalized anxiety disorder. It is also used to treat depression in a different form such as an antidepressant. Dosing is determined by weight, and Strattera is taken once a day with or without food. Children ages 6 and older taking Strattera have been successful in managing weight by taking dosing related side effects as well.
The most common side effects of Strattera are as follows:
If you experience any of these symptoms, they are unlikely to be Strattera side effects, and you should seek medical help immediately.
USES AND Suses:
Major depressive disorder:Major depressive disorder is a condition when you have either:
depressive symptoms that last for a long time. You may have had one or several major depressive disorder (MDD) symptoms for a variety of months.
MDD symptoms that occur 2 or fewer years before your first attack of depression. You may have had one or several MDD symptoms for a short period of time. You may not have experienced any kind of depression symptoms for a long time.
ACL AND GLUT stamina:
Acid reflux disease:
Dysautonomia:
Heartburn:
Liver problems:
Hypersensitivity:
Pneumonia:
Severe diarrhea:
Thyroid problems:
Anxiety disorders:
oping disorders:
sensitivity to light or other substances
Strattera does not usually cause weight gain. The typical weight gain will be around 5 lbs. and the weight loss may last for 10 to 12 months, depending on the severity of the weight gain and the age of the family.
A long-acting non-stimulant that is taken as a capsule and is also an effective treatment for attention-deficit/hyperactivity disorder (ADHD). It also helps a person with ADHD take more exercise to get the most rest. It is not usually known if the non-stimulant medicine is effective for adults with ADHD.
The U. S. version of the drug is the generic drug atomoxetine.
The market for Strattera, a medication used in the treatment of attention deficit hyperactivity disorder, is is now stable. The market for atomoxetine hydrochloride, a type of drug known as a selective norepinephrine reuptake inhibitor, is now valued at approximately USD 3.1 billion and is experiencing significant growth.
The Strattera Stradtkeine (atomoxetine hydrochloride) market was valued at USD 6.2 billion in 2023 and is expected to reach USD 7.2 billion by 2033, growing at a Compound Annual Growth Rate (CAGR) of 4.9% from 2024 to 2033[1].
The market was valued at USD 7.1 billion in 2023 and is expected to reach USD 10.5 billion by 2031, growing at a CAGR of 4.6% from 2024 to 2033[1].
The North American market is valued at USD 0.95 pertainy at the Black Box Pharmacy, primarily used as a add-on treatment for anxiety disorders. This move to North America is driven by the availability of generic versions of Strattera, which has led to a sharp increase in demand for its approval[3].
The European market is valued at USD 0.70 pertainy at the XLPharmacy, primarily used as a add-on treatment for panic disorder. This growth is made possible by the presence of generic versions of Strattera, which are also beginning to show clinical benefits[3].
The Asia-Pacific region is expected to hold steady strength over the forecast period, driven by rising urbanization, rising healthcare expenditure, and an increasing variety of innovative technologies. This increase in demand is not just in generic forms but also in a generic version of Strattera, which will further contribute to this growth[3].
In 2023, about half of the BMC AIDS treatment HIV infected individuals (IHIMS) were hospitalised withataliea HIV infections, with a lion's share from the BMC's focus on secondary prevention[5].
The market is segmented into market1 market2 market3 market3 Market Enhancement (MA/WA). The 3 Market Enhancement segments (e.g. Price of Atomoxetine HCl, MA/WA) are also categorized based on price.3 Market Enhancement market was valued at USD 0.50 pertainy at the BMC AIDS price, primarily used for IHIMS[5].
The fast-acting skeletal muscle relaxants mirtazapine hydrochloride, for example, were found to be key drivers. These drugs are effective in slowing down the worsening of IHIMS and MPORT symptoms, thereby increasing the market's share and earning them a black-box label[5].
The market is competitive with the following:
The market is poised for steady growth, driven by increasing awareness of non-selective antidepressants and increasing healthcare spending. Additional areas that need to be taken frequentNotice the market is expected to be key against these trends[5].
Strattera (Strattera, 10MG, DIFFICULIN TRIHYDRATE) is a nonstimulant medicine that works differently from other types of medicines. It is not considered to be a controlled substance and is therefore not classified as a controlled substance.
Strattera is an anti-psychotic medication that belongs to the methylphenidate class of non-stimulant medicines.
It is available in two strengths: 10mg and 25mg.
This medicine is also used to treat attention deficit hyperactivity disorder, and is also used to treat oppositional defiant disorder.
Strattera belongs to the methylphenidate class of non-stimulant medicines and is classified as a stimulant medicine. It works by increasing the levels of certain chemicals in the brain.
Strattera is available as a capsule or tablet in three strengths: 10mg, 25mg, and 50mg.
Strattera belongs to the group of medicines called methylphenidate.
The stimulant medicine is also known as a nonstimulant medicine. It is not considered to be a controlled substance.
Strattera is available in three strengths: 10mg, 25mg, and 50mg.
The medicine must be taken three times a day. It is important to follow the instructions provided by your healthcare professional regarding the dosage and administration of the medicine. Do not take more than the recommended dose.
Do not crush, chew, or break the tablets.
Strattera is contraindicated in the following situations:
Strattera should not be taken by children or adolescents, because it may increase the risk of seizures in the elderly.
Strattera is generally well tolerated in the general population. However, some side effects can be bothersome and may include:
There are no significant interactions with other medicines or with other treatments. Strattera may interact with other drugs and substances. Therefore, it is advisable to avoid taking Strattera with other medicines.
Stade de France Pharmacy